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• The Toxicology Investigator’s Consortium
(ToxIC) database was created in 2010 by the
American College of Medical Toxicology
(ACMT) to compile data recorded by medical
toxicologists in both inpatient and outpatient
settings.
• In January, 2017 the data field for
transgender (and if transgender, male-tofemale or female-to-male) was added to the
ToxIC form.
• Little is known regarding self-harm
poisonings within the transgender population
• The aim of this study was to review
toxicology consultations around poisonings
in transgender patients, and provide
descriptive data in trends among those
within this demographic.

Problem Statement
The aim of this study was to review medical
encounters due to poisonings and provide
descriptive data in trends among those within
the transgender demographic.

• This study is a retrospective
database review of patient cases
submitted to the ACMT ToxIC
database between January 2017 and
June 2019, who reporting toxicologist
identified as transgender
• Patient cases were considered to
have complete data if the sex
variable was complete as
“transgender.”
• However, within the 113 cases that
had this variable completed as
“transgender,” one was missing the ‘if
transgender” variable specifying
male-to-female, female-to-male, or
gender nonconforming, resulting in
112 cases with this variable
completed.

• The database query identified 113
transgender patients.
• Fifty-one (45.1%) of the 113 were
between 13–18 years old and 60
(53.1%) were aged 19–65 years old.
There was 1 patient who identified as
being between 7–12 years old and 1
between 66–89 years old.
• The primary reason for the encounter
for 97 of the patients was for intentional
pharmaceutical ingestion, and of these
encounters, 85 (87.6%) were classified
as intentional pharmaceutical use
intended for self-harm.
• Among the 51 patients aged 13–18, 46
(90.2%) identified attempt at self-harm
with pharmaceutical as primary reason
for encounter.
• Within the 60 patients aged 19–65, 37
(61.7%) identified primary reason for
encounter as attempted self-harm with
pharmaceutical.
• Excluding missing data, of the 113
patients, 41 (36.3%) were recorded as
male-to-female, 68 (60.2%) female-tomale and 3 (2.7%) as gendernonconforming.
• In the 41 male-to-female transgender
patients, 28 (68.3%) identified the
encounter was for intentional self-harm
with a pharmaceutical agent.
• Of the 68 female-to-male transgender
patients, 53 (77.9%) identified the
primary reason for encounter as intent
for self-harm with a pharmaceutical
agent.

• Drug overdoses and outcomes in the
transgender population represent a
significant gap in the existing literature
• Current studies consistently indicate
that this population is at an increased
risk of suicide
• In our study (albeit small), 90.2% of
transgender patients within the age
group of 13–18 years old reported
attempt at self-harm as the primary
reason for encounter.
• Our study is consistent with prior
research, which describes a difference
in rates of suicidal behavior between
female-to-male adolescents, male-tofemale adolescents, and those who
identify as not exclusively male or
female; all three of these subgroups
have higher suicide rates than male or
female adolescents

• Most toxicological consults in this
cohort of transgender patients were for
intentional pharmaceutical use intended
for self-harm.
• In this small sample there were some
age and transition differences in
prevalence.
• Data describing sex and genderspecific differences in types of
exposures/ingestions, as well as
outcomes, may inform poisoning
prevention practices as well as sex and
gender-based management of patients.
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